{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["199(5)"],"submitter":["Copland M"],"pubmed_abstract":["Despite the success of BCR-ABL-specific tyrosine kinase inhibitors (TKIs) such as imatinib in chronic phase (CP) chronic myeloid leukaemia (CML), patients with blast phase (BP)-CML continue to have a dismal outcome with median survival of less than one year from diagnosis. Thus BP-CML remains a critical unmet clinical need in the management of CML. Our understanding of the biology of BP-CML continues to grow; genomic instability leads to acquisition of mutations which drive leukaemic progenitor cells to develop self-renewal properties, resulting in differentiation block and a poor-prognosis acute leukaemia which may be myeloid, lymphoid or bi-phenotypic. Similar advances in therapy are urgently needed to improve patient outcomes; however, this is challenging given the rarity and heterogene"],"journal":["British journal of haematology"],"pagination":["665-678"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9796596"],"repository":["biostudies-literature"],"pubmed_title":["Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity."],"pmcid":["PMC9796596"],"pubmed_authors":["Copland M"],"additional_accession":[]},"is_claimable":false,"name":"Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.","description":"Despite the success of BCR-ABL-specific tyrosine kinase inhibitors (TKIs) such as imatinib in chronic phase (CP) chronic myeloid leukaemia (CML), patients with blast phase (BP)-CML continue to have a dismal outcome with median survival of less than one year from diagnosis. Thus BP-CML remains a critical unmet clinical need in the management of CML. Our understanding of the biology of BP-CML continues to grow; genomic instability leads to acquisition of mutations which drive leukaemic progenitor cells to develop self-renewal properties, resulting in differentiation block and a poor-prognosis acute leukaemia which may be myeloid, lymphoid or bi-phenotypic. Similar advances in therapy are urgently needed to improve patient outcomes; however, this is challenging given the rarity and heterogene","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-22T10:12:10.18Z","creation":"2025-04-05T23:28:09.352Z"},"accession":"S-EPMC9796596","cross_references":{"pubmed":["35866251"],"doi":["10.1111/bjh.18370"]}}